Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

253
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
253
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cognitive demands of bipedal locomotion during human foraging.

Proceedings. Biological sciences·2026
Same author

A prospective study of 12-month survival of patients with cirrhosis admitted to intensive care.

Internal medicine journal·2026
Same author

A novel clip treatment for gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.

Endoscopy·2026
Same author

The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensus.

Hepatology communications·2026
Same author

Long-term outcomes of surveillance or endoscopic therapy for low-grade dysplastic Barrett's according to a selective management algorithm.

Endoscopy international open·2026
Same author

Nontarget embolization of the hepatic falciform artery in the treatment of hepatocellular carcinoma: Case report and review of the literature.

Radiology case reports·2026

Related Experiment Video

Updated: Jan 15, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.6K

Liraglutide-Induced Liver Injury: A Case Report and Review.

Mark Lai1,2, Patrick Hosking3, Rohit Sawhney1,2

  • 1Department of Gastroenterology, Eastern Health, Melbourne, VIC, Australia.

Case Reports in Gastroenterology
|October 9, 2025
PubMed
Summary

Glucagon-like peptide-1 receptor agonists, like liraglutide, can cause rare drug-induced liver injury (DILI). This case highlights DILI from liraglutide, which resolved after stopping the medication.

Keywords:
Glucagon-like peptide-1 receptor agonistsHepatitisHepatotoxicity

More Related Videos

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.2K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.4K

Related Experiment Videos

Last Updated: Jan 15, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.6K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.2K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.4K

Area of Science:

  • Pharmacology
  • Hepatology
  • Endocrinology

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes and obesity.
  • Liraglutide is a common GLP-1 RA with a generally favorable safety profile.

Purpose of the Study:

  • To report a case of drug-induced liver injury (DILI) associated with liraglutide use.
  • To emphasize the importance of considering DILI in patients on liraglutide presenting with liver abnormalities.

Main Methods:

  • A case presentation of a 30-year-old woman with suspected liraglutide-induced liver injury.
  • Histological confirmation of DILI.
  • Monitoring of liver function tests after drug cessation.

Main Results:

  • The patient developed DILI, confirmed histologically, attributed to liraglutide.
  • Liver injury resolved completely within 6 months of discontinuing liraglutide.
  • This suggests a potential, albeit rare, hepatotoxic effect of liraglutide.

Conclusions:

  • Drug-induced liver injury is a rare but significant adverse effect of liraglutide.
  • Clinicians should be vigilant for DILI in patients treated with liraglutide, especially those with unexplained liver enzyme elevations.
  • Histological examination and drug withdrawal are crucial for diagnosis and management.